Navigation Links
Novel vaccine concept developed by scientists at the Wistar Institute
Date:1/31/2008

(PHILADELPHIA) Creating vaccines to protect people against viral diseases like AIDS, cervical cancer and infectious hepatitis is a delicate balancing act: If the immune systems response to the vaccine is too strong, toxic side effects can kill the patient. If its not strong enough, the virus will spread faster than the immune system can kill it.

A new vaccine design strategy developed by scientists at The Wistar Institute Vaccine Center could be the answer. The secret is using a herpes simplex protein called glycoprotein D to block a specific receptor molecule on antigen-presenting cells, or APCs. These sentinel cells monitor the body for foreign antigens molecules that can stimulate an immune response from invading viruses.

When they detect viral antigens, APCs signal the bodys immune system to activate T cells to attack and destroy cells infected with the virus. At the same time, they also send inhibitory signals to prevent overreaction by the immune system. One of thee inhibitory signals is blocked by glycoprotein D from herpes virus.

In a study that will be published February 6 in Nature Medicine and is available online, Wistar scientists showed that vectors, which are vaccine delivery systems, made by fusing the glycoprotein D with genes from target antigens increase the immune systems response to those antigens in cell cultures and laboratory mice. The researchers used antigens from HIV, the virus that causes AIDS, and from HPV-16, a human papilloma virus that causes cervical cancer.

Hildegund C.J. Ertl, M.D., director of The Wistar Institute Vaccine Center and senior author of the study, says using glycoprotein D to deliver antigens has a major advantage over other vaccine approaches. It allows us to lower the dose but still get a stronger immune response, she says.

Glycoprotein D is part of the herpes viral envelope and is expressed on the surface of cells infected with the herpes simplex virus. Glycoprotein D binds to a receptor molecule called HVEM (herpes virus entry mediator) on antigen-presenting cells. By locking onto the HVEM receptor, glycoprotein D prevents HVEM from binding to another molecule called BTLA on T and B lymphocytes white blood cells that attack disease-causing pathogens.

Binding between HVEM and BTLA is the first step in an inhibitory signaling pathway that reduces the immune systems response to the presence of a virus. Blocking this inhibitory pathway allows the body to mount a stronger immune response by generating more antigen-specific CD8+ T cells to attack cells infected with the virus.

The researchers found that fusing HIV and HPV antigens to glycoprotein D enhances the immune response to those antigens. Mice injected with vaccines that included antigens fused to glycoprotein D generated more virus-killing CD8+ T cells than mice injected with the same vaccines and antigens, but without the glycoprotein D carrier protein.

Researchers also inoculated identical strains of laboratory mice with vaccines containing genes for the cancer-causing proteins E7, E6 and E5 from the HPV-16 virus. One group of animals received HPV-16 genes spliced into the genetic code for glycoprotein D; another group received the same antigens without glycoprotein D. Ten to 14 days later, both groups of animals were injected with a fast-growing tumor cell line that normally generates extensive tumors in mice within 14 days.

Mice that received vaccines with the glycoprotein D-antigen combination were fully protected against cancer, says Wistars Marcio Lasaro, Ph.D., lead author of the study. However, mice inoculated with vaccines containing the same HPV-16 genes, but without glycoprotein D, developed tumors after being inoculated with the same tumor cell line.

Its important to point out that the molecules we targeted in mice are similar to those in humans, and all the basic in-vitro studies in the paper were done with human molecules, making it likely that the method will also work in people, Lasaro says.

Ertl says the ability of the glycoprotein D carrier protein to enhance the immune response could be particularly important to the development of a long-sought vaccine for AIDS. The problem with HIV vaccines is that they might look good in mice and primates, but comparable doses in humans are too toxic, she says. If you lower the dose to avoid toxic side effects, you dont get the immune response you need. She believes that using glycoprotein D may solve that problem.

Ertl and her colleagues are planning future studies to further elucidate the mechanism behind the carrier proteins effectiveness. If studies in research animals continue to be positive, they hope to conduct human clinical studies with HIV and HPV vaccines currently under development at The Wistar Institute Vaccine Center.

The Wistar Institute has filed for patent protection on the glycoprotein D carrier protein technology.


'/>"/>

Contact: Abbey Porter
aporter@wistar.org
215-898-3943
The Wistar Institute
Source:Eurekalert

Related medicine news :

1. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
2. Novel virus detection identifies new viruses in study of respiratory infections and asthma attacks
3. Researchers uncover novel mechanism that balances the sizes of functional areas in the brain
4. Novel Cooling Therapy May Have Aided Injured Football Player
5. ECLIPSE data on effects of Otsukas investigational novel treatment, Tolvaptan
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. GrantAdler Shipping Novel Implantable Vascular Access Port
8. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
9. Novel strategy under study for aggressive leukemia
10. ISTO Technologies Receives 510(k) Clearance for a Novel Bone Graft Substitute and Bone Graft Extender
11. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can be time ... preset onto their media," said Christina Austin - CEO of Pixel Film Studios. ... and easily add stylish color grades to their footage. A LUT is a Lookup ...
(Date:5/28/2016)... ... ... of the city where’s it’s easy to spot the neon lights of chains serving fast ... diners with a taste for real food. , On May 13, the Best ... urban casual restaurant focusing on dishes made by hand with wholesome, organic ingredients that are ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon ... to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel ... year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program at ...
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent of acute stroke ... a sustainable product to aid in the rehabilitation process has steadily increased. Ekso Bionics ... individuals with hemiplegia due to stroke. , Ekso Bionics has now received clearance from ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... educate the many who are unaware of the plight of aphasia. In collaboration ... within the “Stroke Awareness” campaign. , The link between stroke and aphasia is ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... 27, 2016 Hutchison China ... focused on the highly lucrative global oncology and ... of potential first-in-class or best-in-class tyrosine kinase inhibitor ... with strategic partners. HCM,s profitable Chinese healthcare business ... We expect progress of the mid-to-late-stage pipeline during ...
(Date:5/26/2016)... , May 26, 2016 A ... growth is the emergence of new treatments. Cardax, a ... for osteoarthritis treatment. The therapy is expected to fulfil ... Research UK is conducting studies to develop new treatments ... where the genes involved in osteoarthritis are being investigated, ...
(Date:5/25/2016)... 25, 2016 According to a ... (3D, 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), ... (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast to 2021", ... Animation Market for the forecast period of 2016 to ... Million by 2021 from USD 117.3 Million in 2016, ...
Breaking Medicine Technology: